Actavis Files ANDA to Market Generic Version of AbbVie's Androgel

 Actavis, Inc.

today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1.62%.  Actavis' ANDA product is a generic version of AbbVie Inc.'s AndroGel ^ ® 1.62%, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.